Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 3Carcinoma in Situ 1

Interventions

Magnetic Resonance Imaging 2Interferon beta-1b 2Electrocardiography 2Diphenhydramine 2Acetaminophen 2valrubicin 1pembrolizumab 1fludarabine phosphate 1fludarabine 1durvalumab 1dodecyl maltoside 1apaziquone 1aldesleukin 1Tomography, X-Ray Computed 1Respiratory Function Tests 1Proflavine 1Prochlorperazine 1Positron-Emission Tomography 1Ondansetron 1O(6)-codeine methyl ether 1Nicotine Replacement Therapy 1Meperidine 1Mastectomy, Subcutaneous 1Loperamide 1Interleukin-2 1Innovar 1Indomethacin 1Imiquimod 1Hydroxyzine 1Histamine Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Carcinoma in Situ × apaziquone × Clear all
NCT00141531 2012-06-14

Phase II Trial of EOquin in High-risk Superficial Bladder Cancer

Spectrum Pharmaceuticals, Inc

Phase 2 Completed
53 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma in Situ

Data powered by HemOnc (CC BY 4.0) Colophon âš¡